Abstract
Attempts have been made by conventional gene therapy to suppress hepatic fibrogenesis, but potential oncogenic activity may prevent its clinical use. Recently, a novel major approach has been developed for resolution of liver fibrosis and cirrhosis: inactivation of hepatic stellate cells (HSC) using the endogenous expressing gene, which could mediate the homeostatic adaptation of liver. Cytoglobin (Cygb), originally identified in cultured rat HSC, is in a new class of heme containing proteins known as the hexacoordinate globin superfamily. These proteins exhibit peroxidase activity against hydrogen peroxides and lipid hydroperoxides. Considerable attention has been focused on the potential benefits of use of Cygb in fibrosis therapy, as up-regulation of Cygb expression could reduce oxidant stress, suppress HSC differentiation to a myofibroblast-like phenotype and eventually prevent the progress of liver fibrosis. Cygb has also been found to be a candidate tumor suppressor gene that might provide a new option for cancer gene therapy. In this review we systematically analyze the potential of Cygb as a prospective gene medicine for curing fibrosis, cancer, and other diseases such as diabetes. The molecular structure, regulation and subcellular location of Cygb are reviewed as well.
Keywords: Hexacoordination, oxidative stress, hypoxia, up-regulation, stellate cell, tumor suppressor, hypermethylated, gene therapy
Current Gene Therapy
Title: Cytoglobin:A Novel Potential Gene Medicine for Fibrosis and Cancer Therapy
Volume: 8 Issue: 4
Author(s): Yinghui Lv, Qizhao Wang, Yong Diao and Ruian Xu
Affiliation:
Keywords: Hexacoordination, oxidative stress, hypoxia, up-regulation, stellate cell, tumor suppressor, hypermethylated, gene therapy
Abstract: Attempts have been made by conventional gene therapy to suppress hepatic fibrogenesis, but potential oncogenic activity may prevent its clinical use. Recently, a novel major approach has been developed for resolution of liver fibrosis and cirrhosis: inactivation of hepatic stellate cells (HSC) using the endogenous expressing gene, which could mediate the homeostatic adaptation of liver. Cytoglobin (Cygb), originally identified in cultured rat HSC, is in a new class of heme containing proteins known as the hexacoordinate globin superfamily. These proteins exhibit peroxidase activity against hydrogen peroxides and lipid hydroperoxides. Considerable attention has been focused on the potential benefits of use of Cygb in fibrosis therapy, as up-regulation of Cygb expression could reduce oxidant stress, suppress HSC differentiation to a myofibroblast-like phenotype and eventually prevent the progress of liver fibrosis. Cygb has also been found to be a candidate tumor suppressor gene that might provide a new option for cancer gene therapy. In this review we systematically analyze the potential of Cygb as a prospective gene medicine for curing fibrosis, cancer, and other diseases such as diabetes. The molecular structure, regulation and subcellular location of Cygb are reviewed as well.
Export Options
About this article
Cite this article as:
Lv Yinghui, Wang Qizhao, Diao Yong and Xu Ruian, Cytoglobin:A Novel Potential Gene Medicine for Fibrosis and Cancer Therapy, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160656
DOI https://dx.doi.org/10.2174/156652308785160656 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protease Inhibitors in the Clinic
Medicinal Chemistry Bioinformatics Approaches for Anti-cancer Drug Discovery
Current Drug Targets Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism A Novel Adaptive PET/CT Image Fusion Algorithm
Current Bioinformatics Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery An Updated Portrait of Pathogenesis, Molecular Markers and Signaling Pathways of Hepatocellular Carcinoma
Current Pharmaceutical Design Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Accessing Targeted Nanoparticles to the Brain: The Vascular Route
Current Medicinal Chemistry Drug Resistance in Renal Tumors of Childhood
Current Pharmaceutical Biotechnology The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells
Current Cancer Drug Targets Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein
Anti-Cancer Agents in Medicinal Chemistry Solid-State Structure of Abeta (Aβ) in Alzheimer's Disease
Protein & Peptide Letters B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine High-Content Screening and Mechanism-Based Evaluation of Estrogenic Botanical Extracts
Combinatorial Chemistry & High Throughput Screening Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic
Current Pharmaceutical Design